van de Donk NWCJ - Search Results

1

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

Holthof LC, van der Horst HJ, van Hal-van Veen SE, Ruiter RWJ, Li F, Buijze M, Andersen MN, Yuan H, de Bruijn J, van de Donk NWCJ, Lokhorst HM, Zweegman S, Groen RWJ, Mutis T. Holthof LC, et al. Among authors: van de donk nwcj, van hal van veen se, de bruijn j, van der horst hj. Haematologica. 2020 Jan 31;105(2):e80-e83. doi: 10.3324/haematol.2018.213314. Print 2020. Haematologica. 2020. PMID: 31123033 Free PMC article. No abstract available.

2

Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.

de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. de Weerdt O, et al. Neth J Med. 2001 Aug;59(2):50-6. doi: 10.1016/s0300-2977(01)00140-1. Neth J Med. 2001. PMID: 11476912 Clinical Trial.

3

Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy.

Eurelings M, Notermans NC, Van de Donk NW, Lokhorst HM. Eurelings M, et al. Muscle Nerve. 2001 Oct;24(10):1295-302. doi: 10.1002/mus.1147. Muscle Nerve. 2001. PMID: 11562908

4

Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors.

Van De Donk N, De Weerdt O, Eurelings M, Bloem A, Lokhorst H. Van De Donk N, et al. Leuk Lymphoma. 2001 Aug;42(4):609-18. doi: 10.3109/10428190109099321. Leuk Lymphoma. 2001. PMID: 11697489

5

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells.

van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. van de Donk NW, et al. Leukemia. 2002 Jul;16(7):1362-71. doi: 10.1038/sj.leu.2402501. Leukemia. 2002. PMID: 12094262

6

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.

van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM. van de Donk NW, et al. Leukemia. 2003 Jan;17(1):211-9. doi: 10.1038/sj.leu.2402768. Leukemia. 2003. PMID: 12529680

7

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.

van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem AC. van de Donk NW, et al. Blood. 2003 Nov 1;102(9):3354-62. doi: 10.1182/blood-2003-03-0970. Epub 2003 Jul 10. Blood. 2003. PMID: 12855556 Free article.

8

Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.

van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel B, Bloem AC, Lokhorst HM. van de Donk NW, et al. Clin Cancer Res. 2003 Nov 15;9(15):5735-48. Clin Cancer Res. 2003. PMID: 14654559

9

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma.

Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, Cornelissen JJ, Schattenberg AV. Lokhorst HM, et al. Blood. 2004 Jun 1;103(11):4362-4. doi: 10.1182/blood-2003-11-3862. Epub 2004 Feb 19. Blood. 2004. PMID: 14976044 Free article.

10

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.

van de Donk NW, de Weerdt O, Veth G, Eurelings M, van Stralen E, Frankel SR, Hagenbeek A, Bloem AC, Lokhorst HM. van de Donk NW, et al. Leukemia. 2004 Jun;18(6):1078-84. doi: 10.1038/sj.leu.2403363. Leukemia. 2004. PMID: 15085157 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page